Childhood Myelodysplastic Neoplasms
Myelodysplastic Neoplasms in children and adolescents
TREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Childhood Myelodysplastic Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 5, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence.[2] This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Primary care physicians.
Pediatric surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[3] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 3 · NCI website
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Childhood Myelodysplastic Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 5, 2024. Captured 2026-09-09.
Treatment options for children with myelodysplastic neoplasms (MDS) include the following:
Hematopoietic stem cell transplant (HSCT) with or without chemotherapy.
Other therapies.
Sources: Other therapies
Source: Childhood Myelodysplastic Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 5, 2024. Captured 2026-09-09.
MDS and associated disorders usually involve a primitive hematopoietic stem cell. Thus, allogeneic HSCT is considered the optimal approach to treatment for pediatric patients with MDS. Although matched sibling donor transplant is preferred, similar survival has been noted with well-matched, unrelated cord blood and haploidentical approaches.[1-5]
Because survival after HSCT is improved in children with early forms of MDS (refractory anemia), transplant before progression to late MDS or acute myeloid leukemia (AML) should be considered. HSCT should especially be considered when transfusions or other treatments are required, as is usually the case in patients with severe symptomatic cytopenias.[4,6] The 8-year disease-free survival (DFS) rates for children with various stages of MDS has been reported to be 65% for those treated with HLA matched donor transplants and 40% for those treated with mismatched unrelated donor transplants.[6][Level of evidence C2] A 3-year DFS rate of 50% was reported with the use of unrelated cord blood donor transplants for children with MDS when the transplants were done after the year 2001.[7][Level of evidence C2]
Sources: 4 · 6 · 6 · Level of evidence C2 · 7 · Level of evidence C2
When making treatment decisions, certain data should be considered, including the question of whether chemotherapy should be used in high-risk MDS. For example, survival rates as high as 80% have been reported for patients with early-stage MDS who proceeded to transplant within a few months of diagnosis. Additionally, early transplant and no pretransplant chemotherapy have been associated with improved survival in children with MDS.[8][Level of evidence C1]; [9] A retrospective analysis suggested that azacitidine and venetoclax may have a role in the cytoreduction of disease before HSCT in children with MDS. To date, reports of patients with advanced MDS who received venetoclax-based therapy are anecdotal.[10] While results differ in published series, this regimen might prove to be an effective bridge to HSCT. Azacitidine and venetoclax are being prospectively studied as treatment options for children with MDS.
Sources: 8 · Level of evidence C1 · 9 · 10
DFS rates have been estimated to be 50% to 70% for pediatric patients with advanced MDS using myeloablative transplant preparative regimens.[4,6,11-13] While nonmyeloablative preparative transplant regimens are being tested in patients with MDS and AML, such regimens are still investigational for children with these disorders. However, these regimens may be reasonable in the setting of a clinical trial or when a patient’s organ function is compromised in such a way that a myeloablative regimen would be intolerable.[14-17]; [18][Level of evidence C1]
Sources: 4 · 6 · 11 · 13 · 14 · 17 · 18 · Level of evidence C1
Evidence (HSCT):
The Children's Cancer Group 2891 trial accrued patients between 1989 and 1995, including children with MDS.[11] There were 77 patients enrolled, including patients with refractory anemia (n = 2), refractory anemia with excess blasts (RAEB) (n = 33), refractory anemia with excess blasts in transformation (RAEB-T) (n = 26), or AML with antecedent MDS (n = 16). Patients were randomly assigned to receive either standard or intensively timed induction. Subsequently, patients were allocated to allogeneic HSCT if there was a suitable family donor or randomly assigned to either autologous HSCT or chemotherapy.
Sources: 11
The Children's Cancer Group 2891 trial accrued patients between 1989 and 1995, including children with MDS.[11] There were 77 patients enrolled, including patients with refractory anemia (n = 2), refractory anemia with excess blasts (RAEB) (n = 33), refractory anemia with excess blasts in transformation (RAEB-T) (n = 26), or AML with antecedent MDS (n = 16). Patients were randomly assigned to receive either standard or intensively timed induction. Subsequently, patients were allocated to allogeneic HSCT if there was a suitable family donor or randomly assigned to either autologous HSCT or chemotherapy.
Patients with refractory anemia or RAEB had a lower remission rate (45%). Patients with RAEB-T (69%) or AML with a history of MDS (81%) had similar remission rates compared with those with de novo AML (77%).
The 6-year survival rates were lower for those with refractory anemia or RAEB (28%) and RAEB-T (30%).
Patients with AML and antecedent MDS had a similar outcome to those with de novo AML (survival rates, 50% vs. 45%, respectively).
Allogeneic HSCT appeared to improve survival (P = .08).
Based on the results of the EWOG-MDS 98 study, HSCT was verified as an important therapeutic approach necessary to achieve prolonged survival. For many patients, HSCT is the sole therapy received.[19] Children with RAEB (n = 53), RAEB-T (n = 29), and myelodysplasia-related AML (n = 15) were treated with an HSCT from various sources (related and unrelated) using the preparative regimen of busulfan, cyclophosphamide, and melphalan. Among this group, 73 were treated without the use of intensive therapy before the HSCT preparative regimen.
Sources: 19
Based on the results of the EWOG-MDS 98 study, HSCT was verified as an important therapeutic approach necessary to achieve prolonged survival. For many patients, HSCT is the sole therapy received.[19] Children with RAEB (n = 53), RAEB-T (n = 29), and myelodysplasia-related AML (n = 15) were treated with an HSCT from various sources (related and unrelated) using the preparative regimen of busulfan, cyclophosphamide, and melphalan. Among this group, 73 were treated without the use of intensive therapy before the HSCT preparative regimen.
Children with a diagnosis of RAEB and RAEB-T had equivalent event-free survival (EFS) rates of 63% (95% confidence interval [CI], 49%–77%) and 64% (95% CI, 46%–82%), respectively.
For those with a morphological marrow blast percentage before HSCT of less than 5%, 5% to 20%, or 20% or higher, the EFS rates were 62% (95% CI, 41%–83%), 65% (95% CI, 50%–80%) and 45% (95% CI, 23%–67%), respectively.
In the entire cohort (n = 97), patients who received low-dose therapy or no therapy before the preparative regimen (n = 73) had similar EFS rates compared with those who received prior intensive chemotherapy (58% [95% CI, 46%–70%] vs. 62% [95% CI, 42%–82%]).
The outcomes of patients who received unrelated donor cells were like the outcomes of patients who received matched-family donor cells.
A single-institution retrospective analysis reported on 37 consecutive children with various types of MDS who underwent HSCT using various donor types. Some patients were treated with pre-HSCT chemotherapy (n = 7).[8]
Sources: 8
A single-institution retrospective analysis reported on 37 consecutive children with various types of MDS who underwent HSCT using various donor types. Some patients were treated with pre-HSCT chemotherapy (n = 7).[8]
In multivariate analysis, improved DFS was associated with avoiding pre-HSCT chemotherapy (relative risk [RR], 0.30; P = .03) and a shorter interval (<140 days) between diagnosis and HSCT (RR, 0.27; P = .02).
In the 16 children who did not receive pre-HSCT chemotherapy and underwent transplant fewer than 140 days from diagnosis, the 3-year overall survival (OS) and DFS rates were both 80% (95% CI, 51%–93%).
When analyzing these results, it is important to consider that the subtype RAEB-T is likely to represent patients with overt AML, while refractory anemia and RAEB represents MDS. The World Health Organization classification has omitted the category of RAEB-T, concluding that it is essentially AML.
Because MDS in children is often associated with inherited predisposition syndromes, reports of transplant in small numbers of patients with these disorders have been documented. For example, in patients with Fanconi anemia and AML or advanced MDS, the 5-year OS rate has been reported to be 33% to 55%.[20,21][Level of evidence C1]
Sources: 20 · 21 · Level of evidence C1
While some patients with inherited predisposition syndromes require significant modification of their transplant approaches because of excess toxicity (e.g., Fanconi anemia), other syndromes have no detectable excessive toxicity associated with the transplant process. Inherited GATA2 deficiency is a good example of the latter. One study compared HSCT outcomes of 65 children with GATA2 germline pathogenic variants and MDS with the outcomes of 404 children with MDS and wild-type germline GATA2. Rates of DFS, relapse, and nonrelapse mortality were similar in the two populations.[22]
Sources: 22
Second transplants have also been used in pediatric patients with MDS/myeloproliferative disorders who experience relapse or graft failure. The 3-year OS rates were 33% for those who underwent a second transplant after relapse and 57% for those who underwent a second transplant after initial graft failure.[23][Level of evidence C1]
Sources: 23 · Level of evidence C1
For patients with clinically significant cytopenias, supportive care that includes transfusions and prophylactic antibiotics are considered the standard of care. The use of hematopoietic growth factors can improve the hematopoietic status, but there are concerns that such treatment could accelerate conversion to AML.[24]
Sources: 24
Source: Childhood Myelodysplastic Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 5, 2024. Captured 2026-09-09.
In general, the primary aim for children with newly diagnosed MDS is to rule out AML-associated somatic variants, which would indicate the need to treat according to AML guidelines. Thereafter, the objective should be to provide supportive care while looking for an appropriate donor for HSCT. During this time, close monitoring for the emergence of AML is imperative.[25] Therapies used in adult MDS have not been shown to be beneficial in childhood MDS, likely owing to differences in underlying variant etiologies.
Sources: 25
Other therapies for MDS that have been studied and may be applicable include the following:
Agents such as lenalidomide, an analogue of thalidomide, have been tested based on findings that demonstrated increased activity in the bone marrow of patients with MDS. Lenalidomide has shown the most efficacy in patients with 5q- syndrome, especially those with thrombocytosis. The U.S. Food and Drug Administration approved lenalidomide for use in adults with this finding.[26]
Sources: 26
Source: Childhood Myelodysplastic Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 5, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 5, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of newly diagnosed childhood myelodysplastic syndromes (MDS) may include the following:
Sources: diagnosed · myelodysplastic syndromes
Stem cell transplant using blood stem cells from a donor.
Sources: Stem cell transplant · blood stem cells · donor
Supportive care, including transfusion therapy and antibiotics.
Sources: Supportive care · transfusion · therapy · antibiotics
Steroid therapy.
Sources: Steroid therapy
Lenalidomide therapy, for patients with certain gene changes.
Sources: Lenalidomide · therapy · gene
If the MDS becomes acute myeloid leukemia (AML), treatment will be the same as treatment for newly diagnosed AML.
Sources: acute myeloid leukemia · diagnosed
Myelodysplastic Neoplasms in children and adolescents